Previous 10 | Next 10 |
Voyager Therapeutics (VYGR) said that its partner Neurocrine Biosciences (NBIX) had given it a notice of termination of the Parkinson’s disease portion of their collaboration agreement, effective August 2, 2021.Voyager is evaluating the complete financial impact of the termi...
VYGR's Parkinson's Disease asset partnered with Neurocrine has been put on clinical hold by the FDA. The asset - and the company - has a complicated history of deal making and deal breaking. The clinical hold has put the company's future in question. For further details see:...
Gainers: [[MGNI]] +15.1%. [[SCPS]] +11.4%. [[OCN]] +10.5%. [[CLNE]] +6.9%. [[AMTX]] +4.7%.Losers: [[VYGR]] -11.9%. [[YCBD]] -11.4%. [[SPPI]] -9.4%. [[AHT]] -9.0%. [[ABCL]] -8.7%. For further details see: MGNI, SCPS, YCBD and SPPI among after-hours movers
Neurocrine Biosciences (NBIX) and collaboration partner Voyager Therapeutics (VYGR) have announced that the FDA has put a clinical hold on RESTORE-1 trial evaluating NBIb-1817 (VY-AADC) in Parkinson's disease.The independent Data Safety Monitoring Board has requested additional patient level ...
CAMBRIDGE, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that the U.S. Food and Drug Administration (FDA) has notified Neurocrine Biosciences (Nasdaq: NBIX) that it has placed a clinical hold on the RESTORE-1 clinical trial of NBIb-1817 (...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. A ho...
Neurocrine Biosciences reported disappointing sales of Ingrezza, as disruptions to clinical practice caused by COVID-19 have impacted new prescriptions, refills, and patient compliance. If COVID-19 is the true source of Ingrezza headwinds, quarterly sales growth could be under pressur...
Gainers: Greenland Technologies (GTEC) +170%.Revlon (REV) +86%.Summit Wireless Technologies (WISA) +50%.Trxade Group (MEDS) +29%.Inovio Pharmaceuticals (INO) +23%.Xperi Holding (XPER) +21%.Pulse Biosciences (PLSE) +21%.Aptevo Therapeutics (APVO) +21%.Boqii Holding (BQ) +20%.StarTek (SRT)...
Gainers: Trxade Group (MEDS) +35%, OPKO Health (OPK) +19%, Altimmune (ALT) +17%, Sientra (SIEN) +16%, Fulgent Genetics (FLGT) +8%.Losers: Arena Pharmaceuticals (ARNA) -25%, Voyager Therapeutics (VYGR) -21%, Aurora Cannabis (ACB) -21%, ...
Voyager Therapeutics (VYGR): Q3 GAAP EPS of $2.27.Collaboration revenue of $117.84M (+476.8% Y/Y).Cash, cash equivalents and marketable debt of of $200M.Press Release For further details see: Voyager Therapeutics reports Q3 results
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...